SABR and LuPSMA for mHSPC? Let's talk LUNAR
Update: 2025-11-09
Description
Dr Amar Kishan (Radiation Oncologist, UCLA, USA), made lots of headlines recently when he presented data from the phase II randomised LUNAR trial of SABR +/- LuPSMA in patients with oligometastatic prostate cancer. So we were very happy when he turned up in Melbourne recently and popped into the GU Cast studio for a chat. We discuss metastasis-directed therapy and bring up our favourite Pokemet analogies, and ask should we not just be offering these patients and ADT/ARPI doublet?!
Regular hosts Declan Murphy and Renu Eapen, also joined by Prof Wee Ong, Radiation Oncologist at Alfred Health in Melbourne.
This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson.
Even better on our YouTube channel
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
